Arrowstreet Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Arrowstreet Capital’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,390	Closed	-$340K	–	2597
2020 Q3	$340K	Sell	1,390 -1,716	-55%	-$534K	﹤0.01%	2116
2020 Q2	$894K	Buy	3,106 +1,847	+147%	+$544K	﹤0.01%	1810
2020 Q1	$257K	Buy	+1,259	New	+$401K	﹤0.01%	1677

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital's EIGR Position: Q4 2020 in Review

Arrowstreet Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2020, closing a stake of 1,390 shares — an estimated $340K sold.

Arrowstreet Capital first reported a position in EIGR in Q1 2020 and held it in 3 quarters. The position peaked at $894K in Q2 2020. 91 funds tracked by Wall St. Rank hold EIGR as of Q4 2020.

Arrowstreet Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Arrowstreet Capital sold 1,390 Eiger BioPharmaceuticals, Inc. shares in Q4 2020, an estimated $340K.
Arrowstreet Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2020 and held it in 3 quarters.
Arrowstreet Capital's Eiger BioPharmaceuticals, Inc. position peaked at $894K in Q2 2020.
91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2020.

Based on Arrowstreet Capital's 13F filing for Q4 2020, filed 12 Feb 2021.